Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy, with historically high morbidity and mortality following surgical resection.
Over the past two decades, minimally invasive pancreatic resection (MIPR)-encompassing both laparoscopic and robotic approaches-has emerged as a promising alternative to conventional open techniques, offering potential advantages in perioperative recovery while aiming to maintain oncologic standards.
